Information between 12th September 2025 - 2nd October 2025
Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.
| Division Votes |
|---|
|
15 Sep 2025 - Employment Rights Bill - View Vote Context Emily Darlington voted Aye - in line with the party majority and in line with the House One of 302 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 318 Noes - 170 |
|
15 Sep 2025 - Employment Rights Bill - View Vote Context Emily Darlington voted Aye - in line with the party majority and in line with the House One of 304 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 332 Noes - 160 |
|
15 Sep 2025 - Employment Rights Bill - View Vote Context Emily Darlington voted Aye - in line with the party majority and in line with the House One of 301 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 329 Noes - 163 |
|
15 Sep 2025 - Employment Rights Bill - View Vote Context Emily Darlington voted Aye - in line with the party majority and in line with the House One of 300 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 316 Noes - 172 |
|
15 Sep 2025 - Employment Rights Bill - View Vote Context Emily Darlington voted Aye - in line with the party majority and in line with the House One of 300 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 330 Noes - 158 |
|
15 Sep 2025 - Employment Rights Bill - View Vote Context Emily Darlington voted Aye - in line with the party majority and in line with the House One of 300 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 326 Noes - 160 |
|
15 Sep 2025 - Employment Rights Bill - View Vote Context Emily Darlington voted Aye - in line with the party majority and in line with the House One of 302 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 330 Noes - 161 |
|
15 Sep 2025 - Employment Rights Bill - View Vote Context Emily Darlington voted Aye - in line with the party majority and in line with the House One of 302 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 330 Noes - 161 |
|
15 Sep 2025 - Employment Rights Bill - View Vote Context Emily Darlington voted Aye - in line with the party majority and in line with the House One of 301 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 316 Noes - 161 |
|
15 Sep 2025 - Employment Rights Bill - View Vote Context Emily Darlington voted Aye - in line with the party majority and in line with the House One of 300 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 328 Noes - 160 |
|
15 Sep 2025 - Employment Rights Bill - View Vote Context Emily Darlington voted Aye - in line with the party majority and in line with the House One of 303 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 314 Noes - 178 |
|
15 Sep 2025 - Employment Rights Bill - View Vote Context Emily Darlington voted Aye - in line with the party majority and in line with the House One of 304 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 327 Noes - 164 |
|
16 Sep 2025 - Sentencing Bill - View Vote Context Emily Darlington voted No - in line with the party majority and in line with the House One of 277 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 78 Noes - 292 |
|
16 Sep 2025 - Sentencing Bill - View Vote Context Emily Darlington voted Aye - in line with the party majority and in line with the House One of 278 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 340 Noes - 77 |
| Speeches |
|---|
|
Emily Darlington speeches from: Children with SEND: Assessments and Support
Emily Darlington contributed 1 speech (47 words) Monday 15th September 2025 - Westminster Hall Department for Education |
| Parliamentary Debates |
|---|
|
London Fashion Week: Cultural Contribution
25 speeches (8,739 words) Tuesday 16th September 2025 - Westminster Hall Department for Digital, Culture, Media & Sport Mentions: 1: Samantha Niblett (Lab - South Derbyshire) Friend the Member for Milton Keynes Central (Emily Darlington) is inspiring people, including my office - Link to Speech 2: Rosie Wrighting (Lab - Kettering) Friend the Member for Milton Keynes Central (Emily Darlington). - Link to Speech |
| Select Committee Documents |
|---|
|
Tuesday 16th September 2025
Oral Evidence - DSIT, Office for Life Sciences, and Department of Health and Social Care (DHSC) Science, Innovation and Technology Committee Found: Watch the meeting Members present: Dame Chi Onwurah (Chair); Emily Darlington; George Freeman; Tom Gordon |
|
Tuesday 16th September 2025
Oral Evidence - MSD, ABPI (The Association of the British Pharmaceutical Industry), and AstraZeneca Science, Innovation and Technology Committee Found: Watch the meeting Members present: Dame Chi Onwurah (Chair); Emily Darlington; George Freeman; Tom Gordon |
| Calendar |
|---|
|
Tuesday 14th October 2025 9 a.m. Science, Innovation and Technology Committee - Oral evidence Subject: Innovation showcase At 9:30am: Oral evidence Dr Sebastian Weidt - Co-Founder and CEO at Universal Quantum At 9:45am: Oral evidence Nick Davies - Programme Director at Institute for Government Jason Liggins - CEO at Crown Hosting Data Centres At 10:30am: Oral evidence Gaia Marcus - Director at Ada Lovelace Institute Jeni Tennison - Executive Director at Connected by Data View calendar - Add to calendar |
|
Tuesday 21st October 2025 9 a.m. Science, Innovation and Technology Committee - Oral evidence Subject: Innovation showcase View calendar - Add to calendar |
| Select Committee Inquiry |
|---|
|
2 Oct 2025
Life sciences investment Science, Innovation and Technology Committee (Select) Not accepting submissions With MSD cancelling its £1 billion ongoing manufacturing site in Kings Cross, AstraZeneca pausing its £200 million investment in its Cambridge site, and the latter upgrading its US listing, the Science, Innovation and Technology Committee is launching a call for evidence on UK life sciences competitiveness. This follows an initial emergency session, where it heard from representatives from MSD and AstraZeneca, as well as the ABPI, and from officials and ministers, including Minister for Science, Research and Innovation, Patrick Vallance. The call for written evidence will examine the competitiveness of the UK’s life sciences sector, barriers to innovation for medicines in the UK, issues with pricing uptake and access, and the impact of other countries’ policies. |